The Role of JAK Inhibitors in Atopic Dermatitis: A Guide

Categories:

Last updated: November 2026

JAK Inhibitors in Atopic Dermatitis: Advances in Treatment Care

JAK inhibitors in atopic dermatitis have transformed the treatment landscape for patients with moderate to severe disease, offering faster itch relief and more targeted immune modulation than many traditional therapies. Atopic dermatitis (AD), commonly known as eczema, is one of the most prevalent chronic inflammatory skin diseases in the world, affecting up to 20% of children and 10% of adults worldwide. Characterized by intense itch, skin barrier dysfunction, and recurrent flares of eczematous skin lesions, AD carries a substantial quality-of-life burden that includes sleep disruption, anxiety, depression, and difficulty at school and work. For patients with moderate to severe disease that cannot be controlled with topical therapies and emollients, systemic atopic dermatitis treatment options are now more sophisticated and more numerous than ever before, and at the center of this evolution is a class of medications known as Janus kinase (JAK) inhibitors.

In the US, three JAK inhibitors are FDA-approved for atopic dermatitis: two pills, Rinvoq (upadacitinib) and Cibinqo (abrocitinib), and one cream, Opzelura (ruxolitinib). This guide explains how they work, who they’re for, their side effects and how they compare with biologic injections.

At a Glance: JAK Inhibitors for Atopic Dermatitis in the US

Rinvoq (upadacitinib)Cibinqo (abrocitinib)Opzelura (ruxolitinib)
FormPill, once a dayPill, once a dayCream, twice a day
Eczema severityModerate to severeModerate to severeMild to moderate
AgesAdults, and children 12+ weighing at least 88 lb12 and older2 and older
Used whenOther systemic treatments, including biologics, haven’t worked or aren’t advisedSame as RinvoqOther prescription creams haven’t worked or aren’t advised
FDA boxed warningYesYesYes

Understanding the JAK-STAT Pathway in Atopic Dermatitis

JAK inhibitors in atopic dermatitis work by blocking the Janus kinase family of enzymes: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are essential intermediaries in the signaling pathways of many pro-inflammatory cytokines. In atopic dermatitis, the JAK-STAT pathway is central to the pathology: cytokines, including IL-4, IL-13, IL-31, IL-22, TSLP, and others, bind to receptors on immune and skin cells, triggering JAK activation and downstream inflammatory cascades that cause itch, skin inflammation, and barrier disruption.

By selectively inhibiting JAK1 or broader combinations of JAK family members, JAK inhibitors interrupt these inflammatory signals at a fundamental level. The specificity of different JAK inhibitors matters: JAK1-selective agents like abrocitinib and upadacitinib are designed to target the most relevant inflammatory pathways in AD while minimizing off-target effects that could arise from more broadly inhibiting all JAK family members.

Oral JAK Inhibitors: Upadacitinib and Abrocitinib

Two oral JAK1-selective inhibitors are FDA-approved in the US as new treatments for atopic dermatitis for moderate to severe disease in people 12 and older: upadacitinib (Rinvoq, AbbVie) and abrocitinib (Cibinqo, Pfizer). Both are for patients whose eczema isn’t controlled with other systemic treatments, including biologics, or when those treatments aren’t advisable.

Upadacitinib (15 mg or 30 mg once daily) has consistently demonstrated impressive clinical trial results. In the Measure Up 1 and Measure Up 2 phase 3 trials, both doses of upadacitinib produced statistically significant improvements in IGA scores and EASI-75 (a 75% reduction in eczema area and severity) compared to placebo in patients aged 12 and older with moderate to severe AD. Some patients had less itch as early as 2 days after starting treatment, a particularly important outcome for patients whose quality of life is most severely affected by itch. Some patients continued to see clearer skin for up to 52 weeks while taking it.

Abrocitinib (100 mg or 200 mg once daily) has similarly demonstrated strong efficacy in the JADE MONO-1, JADE MONO-2, and JADE COMPARE phase 3 trials. The JADE COMPARE trial directly compared abrocitinib with dupilumab, the benchmark biologic for AD: abrocitinib 200 mg relieved itch faster than dupilumab at week 2, though it wasn’t better at clearing skin by week 16. For patients who prioritize rapid itch relief, this may be an advantage when weighing biologics vs JAK inhibitors.

Topical JAK Inhibitors: Ruxolitinib and Delgocitinib

For mild to moderate atopic dermatitis, or for people who prefer not to take a pill, a JAK inhibitor cream works right where it’s applied, and much less medicine reaches the bloodstream than with a pill.

Ruxolitinib cream 1.5% (Opzelura) is the only JAK inhibitor cream FDA-approved for atopic dermatitis in the US. It was approved for people 12 and older in 2021 and for children 2 to 11 in September 2025.

  • How it’s used: a thin layer twice a day on up to 20% of the body, for short-term and on-and-off use, when other prescription creams haven’t worked well enough.
  • How well it works: in the TRuE-AD3 trial in children 2 to 11, 56.5% of those using the 1.5% cream were clear or almost clear at week 8, compared with 10.8% using a non-medicated cream.
  • Safety: it carries the same FDA boxed warning as JAK pills. It isn’t recommended together with biologics, other JAK inhibitors or strong immune-suppressing drugs.

Delgocitinib cream (Anzupgo) is a different case. The FDA approved it in July 2025 for moderate to severe chronic hand eczema in adults, the first treatment approved specifically for that condition. It is not approved for atopic dermatitis in the US.

For a side-by-side look at Opzelura and steroid-free creams like Zoryve and Vtama, see our eczema treatment guide.

JAK Inhibitor Side Effects

Most side effects seen in clinical trials of JAK inhibitors for skin conditions were mild. According to the American Academy of Dermatology, the most common include:

  • Common cold and other upper respiratory infections
  • Bronchitis
  • Ear infections
  • Urinary tract infections
  • Headache
  • Nausea

With Opzelura cream, the most common side effects in eczema studies also included hives, inflamed hair pores (folliculitis), diarrhea and irritation or itching where the cream was applied.

Serious but less common side effects are the reason for the FDA boxed warning: serious infections (including tuberculosis and shingles), blood clots, heart attack or stroke, certain cancers, and higher risk of death. Most of this data came from older adults with rheumatoid arthritis and at least one heart risk factor taking a JAK pill. Low blood counts and higher cholesterol can also occur.

Who’s at higher risk: people over 50, current or past smokers, and anyone with a history of heart disease, stroke, blood clots or cancer. Tell your dermatologist about these before starting.

Get medical help right away if you notice signs of infection (fever, cough, painful skin sores), chest pain, sudden weakness on one side, slurred speech, or leg swelling and pain.

Safety Considerations with JAK Inhibitors

While JAK inhibitors in atopic dermatitis have become some of the most important new treatments for atopic dermatitis, they carry a class-related safety profile that requires attention and appropriate patient selection. The FDA requires boxed warnings for JAK inhibitors regarding risks of serious infections, malignancy (particularly lymphoma and non-melanoma skin cancer), major adverse cardiovascular events (MACE), thrombosis, and mortality, primarily derived from data in older patients with rheumatoid arthritis who had at least one heart disease risk factor.

For the younger, healthier population typically seeking atopic dermatitis treatment, the absolute risks are considerably lower, but monitoring is still important. Patients considering systemic JAK inhibitors should work closely with a qualified, board-certified dermatologist to evaluate their individual risk profile, treatment goals, and long-term management strategy.

Recommended pre-treatment screening includes baseline complete blood count with differential, liver enzymes, lipid panel, tuberculosis testing, viral hepatitis screening, and pregnancy test, where applicable. Your dermatologist may recommend bringing vaccines up to date, including the shingles vaccine, before you start, and avoiding live vaccines during treatment. Regular laboratory monitoring during treatment is advised, with specific intervals varying by agent. Clinicians follow current AAD and FDA guidelines for monitoring to help ensure patient safety throughout treatment with JAK inhibitors in atopic dermatitis.

Opzelura cream carries the same boxed warning as JAK pills, although much less medicine reaches the bloodstream. It remains a valuable option for patients who prefer topical treatment or for whom a pill poses greater risks.

Choosing Between JAK Inhibitors and Biologics

A common clinical question involves biologics vs JAK inhibitors for moderate to severe AD. JAK inhibitors are often compared with biologics such as dupilumab (Dupixent) and lebrikizumab (Ebglyss), both of which have become important options in modern atopic dermatitis treatment.

In the head-to-head JADE COMPARE trial, abrocitinib 200 mg relieved itch faster than dupilumab at week 2, though it wasn’t better at clearing skin by week 16. Dupilumab has a longer track record and is also approved for related conditions like asthma and chronic sinusitis with nasal polyps, making it particularly attractive for patients with multiple atopic conditions.

In the US, JAK pills are approved for people whose eczema isn’t controlled by other systemic treatments, including biologics, so many patients try a biologic first. Biologics now include options with fewer shots, such as Ebglyss, which can be given every 8 weeks once eczema is under control.

JAK inhibitors may be preferred in patients who need rapid itch relief, those who have not responded to a biologic, patients who prefer oral over injectable therapy, or individuals whose clinical profile makes a JAK inhibitor well-suited. The expanding range of both topical and systemic options means that individualized decision-making, based on disease severity, patient age, comorbidities, prior therapy, patient preference, and insurance access, is increasingly possible and important.

Atopic Dermatitis Care at Trillium Clinic

Atopic dermatitis is more than a cosmetic nuisance; it is a systemic inflammatory condition with meaningful impact on mental health, sleep, relationships, and productivity. At Trillium Clinic, with offices in Chapel Hill, Smithfield and Burlington, North Carolina, we take a comprehensive approach to AD management that begins with accurate diagnosis, skin care education, and trigger identification, and extends through stepwise escalation to advanced therapies, including both topical and systemic JAK inhibitors in atopic dermatitis and biologics when indicated.

Dr. Stefan Weiss is a board-certified dermatologist and a member of the National Eczema Association. We see patients from across the Triangle and central North Carolina, including Raleigh, Durham, Cary, Hillsborough, Mebane and Greensboro. Learn more about our atopic dermatitis care and the insurance plans we accept.

Our team includes experienced specialists who provide personalized atopic dermatitis treatment and help patients navigate the nuances of JAK inhibitor therapy, including appropriate patient selection, pre-treatment workup, dosing decisions, and long-term monitoring. If you or your child is struggling with atopic dermatitis that has not responded adequately to moisturizers, topical steroids, or other conventional treatments, we encourage you to reach out. A consultation with one of our dermatologists can open the door to a more effective, individualized treatment plan.

Frequently asked questions

They are targeted medications that block inflammatory signaling pathways involved in eczema. By interrupting the JAK-STAT pathway, these treatments help reduce itching, inflammation, and skin barrier dysfunction associated with atopic dermatitis.

Both can work well. JAK pills often relieve itch faster and are taken by mouth. Biologics have a longer track record and also treat related conditions like asthma. In the US, JAK pills are approved for people whose eczema isn't controlled by other systemic treatments, including biologics, so many patients try a biologic first.

JAK pills (Rinvoq, Cibinqo) are for people 12 and older with moderate to severe eczema that other systemic treatments haven't controlled. Opzelura cream is for people 2 and older with mild to moderate eczema when other prescription creams haven't worked. A dermatologist will review your health history and risk factors first.

The most common are colds and other upper respiratory infections, bronchitis, ear and urinary tract infections, headache and nausea. Less common but serious risks, listed in the FDA boxed warning, include serious infections, blood clots, heart attack or stroke and certain cancers. Your dermatologist will check your risk factors and monitor you during treatment.

JAK pills need regular checkups and blood tests while you take them. Some patients in clinical trials kept seeing clearer skin for up to 52 weeks. Opzelura cream is meant for short-term, on-and-off use. Your dermatologist will weigh the benefits and risks for you.

Yes. Opzelura (ruxolitinib) cream is the only JAK inhibitor cream FDA-approved for atopic dermatitis in the US, for people 2 and older with mild to moderate eczema. Much less medicine reaches the bloodstream than with a pill, but it carries the same boxed warning. Anzupgo (delgocitinib) cream is approved only for chronic hand eczema in adults.

About Dr. Weiss

Stefan C. Weiss, MD, FAAD, is a board-certified dermatologist, the medical director of Trillium Clinic and an adjunct professor of dermatology at Brown University. He trained at Duke University School of Medicine and Stanford University Medical Center, has authored more than 100 peer-reviewed abstracts, posters and manuscripts, and has over two decades of experience in medical and cosmetic dermatology.

References

  1. American Academy of Dermatology. JAK inhibitors: what your dermatologist wants you to know.
  2. American Academy of Dermatology. Atopic dermatitis: diagnosis and treatment.
  3. DailyMed (National Library of Medicine). Rinvoq (upadacitinib) prescribing information.
  4. Incyte. Opzelura prescribing information.
  5. Incyte. FDA approval of Opzelura cream in children ages 2 to 11. September 2025.
  6. Incyte. New data for ruxolitinib cream in children with atopic dermatitis (TRuE-AD3). October 2023.
  7. LEO Pharma. FDA approval of Anzupgo (delgocitinib) cream. July 2025.
  8. New England Journal of Medicine. Abrocitinib versus placebo or dupilumab for atopic dermatitis (JADE COMPARE). 2021.
  9. U.S. Food and Drug Administration. JAK inhibitors: drug safety communication. 2021.
  10. Eli Lilly. FDA approves Ebglyss for one maintenance dose every eight weeks. June 2026.

This article is for general education and isn’t a substitute for personal medical advice. A board-certified dermatologist can tell you which treatment is right for you.

About Us

Dr. Stefan C. Weiss, board-certified dermatologist at Trillium Clinic

Trillium Clinic Dermatology and Trillium Med Spa are dedicated to assisting patients embark on a transformative path toward improved wellness, radiant skin, and renewed confidence.

Have a Question?

Please reach out to us today…we look forward to hearing from you. Your path to radiant skin starts here.

Related Blogs

Trillium Clinic Logo